Lilly receives US FDA approval for Retevmo

This article was originally published here

Retevmo was approved under the FDA’s Accelerated Approval regulations based on the LIBRETTO-001 Phase 1/2 trial’s endpoints of objective response rate (ORR) and duration of response (DoR). Continued

The post Lilly receives US FDA approval for Retevmo appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply